Hybrid or multifactorial drugs in antihypertensive treatment.
van Zwieten
P A
PA
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000737:chemistry / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007741:Labetalol / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004338:Drug Combinations; D010879:Piperazines; D012702:Serotonin Antagonists; D014665:Vasodilator Agents; C015568:urapidil; D007741:Labetalol